View Future GrowthEuroespes 過去の業績過去 基準チェック /06Euroespesの収益は年間平均-519.8%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.9% 0.09%割合で 増加しています。主要情報-519.80%収益成長率-565.08%EPS成長率Life Sciences 業界の成長26.83%収益成長率0.085%株主資本利益率-18.34%ネット・マージン-29.49%前回の決算情報31 Dec 2022最近の業績更新更新なしすべての更新を表示Recent updatesNew Risk • Nov 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.67m market cap, or US$3.99m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.2m).New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.46m market cap, or US$3.85m). Minor Risks Share price has been volatile over the past 3 months (4.6% average weekly change). Revenue is less than US$5m (€3.9m revenue, or US$4.3m).New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€3.85m market cap, or US$4.14m). Minor Risk Revenue is less than US$5m (€3.9m revenue, or US$4.1m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Nov 11Would Euroespes (BME:EEP) Be Better Off With Less Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • May 10Here's Why Euroespes (BME:EEP) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Jan 13New 90-day high: €0.48The company is up 2.0% from its price of €0.47 on 14 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 2.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: €0.37The company is down 24% from its price of €0.48 on 24 September 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.Is New 90 Day High Low • Dec 02New 90-day low: €0.40The company is down 17% from its price of €0.48 on 03 September 2020. The Spanish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.収支内訳Euroespes の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BME:EEP 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 224-11030 Sep 224-10030 Jun 22400031 Mar 22400031 Dec 21400030 Sep 21400030 Jun 21300031 Mar 21300031 Dec 20300030 Sep 203-10030 Jun 202-10031 Mar 202-10031 Dec 193-10030 Sep 193-10030 Jun 193-10031 Mar 193-10031 Dec 18300030 Sep 18300030 Jun 18300031 Mar 18300031 Dec 17300030 Sep 17400030 Jun 17400031 Mar 17400031 Dec 16300030 Jun 16300031 Mar 16300031 Dec 15300030 Jun 15300031 Mar 15300031 Dec 14300031 Dec 133000質の高い収益: EEPは現在利益が出ていません。利益率の向上: EEPは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: EEPの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: EEPの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: EEPは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 5.4% ) と比較することは困難です。株主資本利益率高いROE: EEPは現在利益が出ていないため、自己資本利益率 ( -18.34% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/28 01:12終値2023/12/01 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Euroespes, S.A. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Nov 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.67m market cap, or US$3.99m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.2m).
New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.46m market cap, or US$3.85m). Minor Risks Share price has been volatile over the past 3 months (4.6% average weekly change). Revenue is less than US$5m (€3.9m revenue, or US$4.3m).
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€3.85m market cap, or US$4.14m). Minor Risk Revenue is less than US$5m (€3.9m revenue, or US$4.1m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Nov 11Would Euroespes (BME:EEP) Be Better Off With Less Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • May 10Here's Why Euroespes (BME:EEP) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Jan 13New 90-day high: €0.48The company is up 2.0% from its price of €0.47 on 14 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 2.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: €0.37The company is down 24% from its price of €0.48 on 24 September 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Dec 02New 90-day low: €0.40The company is down 17% from its price of €0.48 on 03 September 2020. The Spanish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.